Business
Full Year Results 2015
Full Year Results 2015.
About this update from Niox Group Plc
[{"type":"text","content":"\n \nRNS Number : 7711R Circassia Pharmaceuticals Plc 11 March 2016 \n\nCIRCASSIA PHARMACEUTICALS PLC\n \nPRELIMINARY RESULTS FOR THE YEAR ENDED 31 DECEMBER 2015\n \n- Positioned to deliver -\n- Cat allergy phase III study on track to report Q2 2016 -\n- Acquisitions validated; strong NIOX® sales growth and lead asthma product approved -\n- Fully funded; successful £275 million fundraising completed June 2015 -\n \nOxford, UK - 11 March 2016: Circassia Pharmaceuticals plc (\"Circassia\" or \"the Company\") (LSE: CIR), a specialty biopharmaceutical company focused on allergy and respiratory medicine, today announces its preliminary results for the year ended 31 December 2015.\n \nCommenting on the results, Steve Harris, Circassia's Chief Executive, said: \"Circassia is in a period of exciting transformation as we accelerate our strategy to become a self-sustaining specialty biopharmaceutical company. Our innovative allergy treatments continue to make good progress, and we remain on track to deliver our phase III results in the coming months. During the year, we successfully completed two strategic acquisitions, which give us established specialty commercial infrastructure targeting the key customers for our next-generation allergy immunotherapies, while also significantly broadening our pipeline. Importantly, these acquisitions have been validated by the significant sales growth of our acquired NIOX® products and the approval of our lead asthma treatment. \n \nIn the coming year, we intend to build on this progress, expanding our commercial presence in preparation for the launch of our first allergy treatment, while further increasing sales of our approved products. We also plan to deliver on our wider pipeline, including moving our grass allergy treatment into a registration study. As a result, 2016 will be an important year for Circassia as we move towards our goal of building a leading specialty biopharmaceutical business.\"\n \nOPERATIONAL HIGHLIGHTS\n \nAllergy clinical programmes progressing\n \n· Cat allergy phase III pivotal study (CATALYST) completed last patient dosing; results expected Q2 2016; pre-BLA meeting scheduled with FDA\n· Cat allergy two-to-five year follow-up (CP007A) continuing enrolment; 42...